Kitov Pharma Ltd (KTOV)
Purple Biotech to Present at the B. Riley Oncology Investor Conference
Purple Biotech to Ring the Nasdaq Stock Market Opening Bell
Kitov Announces Name Change to Purple Biotech Ltd.
Kitov Pharma to Participate in November Investor Conferences
Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb
The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer
Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219
New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference
H.C. Wainwright Thinks Kitov Pharmceuticals’ Stock is Going to Recover
Dosing underway in Kitov Pharma's NT219 study in advanced cancer patients (NASDAQ:KTOV)
Kitov Pharma (NASDAQ:KTOV) announces that the first patient has been dosed in the Phase 1/2 clinical trial evaluating NT219 as monotherapy treatment of advanced solid tumors, as well as in combination with cetuximab, for the treatment of recurrent and/or metastatic solid tumors and head and neck cancer or colorectal adenocarcinoma.
Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
Top Line Results from First Part of the Study Expected in Second Half of 2021
Kitov Pharma receives new patents for CM24 and NT219 in China (NASDAQ:KTOV)
Kitov Pharma (NASDAQ:KTOV) announces receipt of notification from the Chinese Patent Office to grant two separate patents for its lead oncology candidates CM24, a monoclonal antibody targeting CEACAM1, and NT219, a dual inhibitor, novel small molecule targeting IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.
PDD, GAN among premarket losers
Gevo (NASDAQ:GEVO) -26% on launch of direct offering; pared down overnight gains after Trafigura deal.GAN (NASDAQ:GAN) -16% on Q2 earnings.Xcel Brands (NASDAQ:XELB) -10%.Pinduoduo (NASDAQ:PDD) -9% on Q2 earnings.Kitov Pharma (NASDAQ:KTOV) -7%.AirNet Technology (NASDAQ:ANTE) -7%.OpGen (NASDAQ:OPGN) -6%.MICT (NASDAQ:MICT) -6%.Top Ships (NASDAQ:TOPS) -5%.iFresh (NASDAQ:IFMK) -6%.Sypris Solutions (NASDAQ:SYPR) -6%.Allied Esports Entertainment (NASDAQ:AESE) -5%.Blink Charging (NASDAQ:BLNK) -5%.AngloGold Ashanti (NYSE:AU) -5% after being told by South African Gov.
Kitov Pharma announces ADS ratio change (NASDAQ:KTOV)
Kitov Pharma (NASDAQ:KTOV) has changed the ratio of its ADSs to ordinary shares from 1 ADS representing 1 ordinary shares to a new ratio of 1 ADS representing 10 ordinary shares.The ratio change will be effective at the beginning of trading on August 21.For ADS holders, the ratio change will have the same effect as a 1/10 reverse ADS split.The ADS ratio change was to enable the Company to regain its compliance as per Nasdaq listing rule.
Kitov Pharma Announces ADS Ratio Change
Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results
Is Kitov Pharmaceuticals Holdings (KTOV) Outperforming Other Medical Stocks This Year?
Is (KTOV) Outperforming Other Medical Stocks This Year?
Are These Penny Stocks To Buy Or Avoid Before The Weekend?
Penny Stocks To Watch Before The End Of The Week
3 Penny Stocks To Buy Under $1.50 Right Now, But For How Long?
Penny Stocks That Can Be Bought For Less Than $1.50 Right Now
Is Kitov Pharmaceuticals Holdings (KTOV) Outperforming Other Medical Stocks This Year?
Is (KTOV) Outperforming Other Medical Stocks This Year?
Kitov Pharma launches mid-stage study of NT219 in solid tumors (NASDAQ:KTOV)
Kitov Pharma (KTOV -6.8%) initiates Phase 1/2 trial of NT219 as monotherapy for advanced solid tumors, as well as in combination with cetuximab, a monoclonal antibody that blocks epithelial growth factor receptor, as a second-line or third-line treatment of recurrent and metastatic squamous cell carcinoma of the Head & Neck CancerSmall molecule NT219 is a dual inhibitor targeting IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.The primary objectives of the trial are to evaluate safety, assess pharmacokinetics, identify the recommended dose, and establish preliminary efficacy of NT219.The company expects to report preliminary data from the first part of the study in second half of 2021.
Kitov Pharma launches early-stage study of NT219 in solid tumors (NASDAQ:KTOV)
Kitov Pharma (KTOV -6.8%) initiates Phase 1/2 trial of NT219 as monotherapy for advanced solid tumors, as well as in combination with cetuximab, a monoclonal antibody that blocks epithelial growth factor receptor, as a second-line or third-line treatment of recurrent and metastatic squamous cell carcinoma of the Head & Neck CancerSmall molecule NT219 is a dual inhibitor targeting IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.The primary objectives of the trial are to evaluate safety, pharmacokinetics, identify the recommended dose, and establish preliminary efficacy of NT219.Preliminary data from the first part of the study should be available in H2 2021.
Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
3 Biotech Penny Stocks To Buy Or Hold According To Analysts
Penny Stocks Analysts Are Bullish On In Biotech
Kitov Pharma +18% on new European patent for anti-CEACAM1 antibody (NASDAQ:KTOV)
The European Patent Office intends to grant a new patent to Kitov Pharma (NASDAQ:KTOV) for application entitled “Humanized antibodies against CEACAM1.”The patent covers protein and DNA sequences pertaining to humanized antibodies capable of specific binding to human CEACAM1 molecules, including monoclonal antibody, CM24, pharmaceutical compositions comprising these antibodies, as well as methods for their use in treating and diagnosing cancer and other conditions.Shares are up 18% premarket.
Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody
Kitov Pharma's strong cash balance (NASDAQ:KTOV)
As of June 2020, Kitov Pharma (KTOV +7.8%) reported +$60M in cash which it plans to use for conducting the two clinical studies to be initiated in 2020. The cash is likely to support company's activit
Kitov Pharma Issues CEO Shareholder Letter Providing Business Update
T2 Biosystems among healthcare gainers; Inovio Pharmaceuticals leads the losers
Gainers: Alterity Therapeutics (NASDAQ:ATHE) +66%. Qualigen Therapeutics (NASDAQ:QLGN) +37%. T2 Biosystems (NASDAQ:TTOO) +37%. Akero Therapeutics (NASDAQ:AKRO) +28%. AxoGen (NASDAQ:AXGN) +24%.Losers: